The first mRNA-based malaria clinical trial tests a single RNA construct encoding part of the P. falciparum circumsporozoite protein (CSP), and the second tests a combination of 3 distinct RNAs—the full P. falciparum CSP and 2 conserved segments of liver stage-expressed proteins—with plans for controlled human malaria infection to determine preliminary vaccine efficacy. Here, DNAJC5 is linked to malaria.